Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
122,470,452
-
Total 13F shares
-
121,424,270
-
Share change
-
+19,415,272
-
Total reported value
-
$2,893,303,857
-
Put/Call ratio
-
5.8%
-
Price per share
-
$23.83
-
Number of holders
-
206
-
Value change
-
+$498,497,157
-
Number of buys
-
137
-
Number of sells
-
65
Institutional Holders of Arcus Biosciences, Inc. - Common Stock (RCUS) as of Q4 2025
As of 31 Dec 2025,
Arcus Biosciences, Inc. - Common Stock (RCUS) was held by
206 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
121,424,270 shares.
The largest 10 holders included
GILEAD SCIENCES, INC., BlackRock, Inc., VANGUARD GROUP INC, SUVRETTA CAPITAL MANAGEMENT, LLC, WELLINGTON MANAGEMENT GROUP LLP, STATE STREET CORP, Woodline Partners LP, MARSHALL WACE, LLP, Point72 Asset Management, L.P., and Siren, L.L.C..
This page lists
206
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.